Biomarkers Market

The global biomarkers market is expected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% between 2026 and 2031. The growth of the global biomarkers market is driven by several key factors, including the rising adoption of precision medicine and companion diagnostics, as well as the growing use of NGS, PCR, proteomics, and multi-omics platforms.

Several key players in the global biomarkers industry include F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), Abbott (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), and Charles River Laboratories (US), among others. Companies in the biomarkers market pursue growth through strategic acquisitions, R&D collaborations, geographic expansions, novel product launches, and investments in multi-omics platforms.

To know about the assumptions considered for the study download the pdf brochure

In June 2026, Roche received FDA approval for the first companion diagnostic assay to assess PTEN protein levels in prostate cancer. The VENTANA PTEN assay enables the identification of patients for more targeted treatment decisions.

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche leads the global biomarkers market with its robust diagnostics portfolio, including NGS platforms and companion diagnostics for oncology and neurology, enabling precise patient stratification. The company’s acquisitions are bolstering its capabilities in cardiometabolic and liver disease biomarkers through innovative NASH therapies. This move enhances Roche's multi-omics offerings, expands partnerships with health systems, and accelerates biomarker-driven precision medicine worldwide.

Thermo Fisher Scientific (US)

Thermo Fisher Scientific, based in the US, is a prominent player in the North American biomarkers market. The company offers a range of products, including integrated next-generation sequencing (NGS) assays, mass spectrometry tools, and multi-omics panels for cancer and infectious disease research. Recent acquisitions have enhanced Thermo Fisher's portfolio by adding advanced imaging biomarkers and eClinical solutions to its biopharma services. These acquisitions strengthen Thermo Fisher's end-to-end biomarker workflow, expand its bioprocessing capabilities, and improve data analytics for clinical trials across various continents.

Merck KGaA (Germany)

Merck is also a leader in the global biomarkers market, leveraging proteomics platforms and liquid biopsy tech for oncology and immunotherapy companion diagnostics. The firm acquired SpringWorks Therapeutics, integrating gamma-secretase inhibitors and expanding its tumor biomarker discovery for solid tumors. This strategic buy deepens Merck's precision oncology pipeline, fosters R&D collaborations, and broadens access to advanced biomarker tests in emerging markets.

Market Ranking

The global biomarkers market is highly consolidated, with leading diagnostics companies facilitating the transition of biomarkers from research to routine clinical care. Roche (Switzerland) leverages its extensive portfolio of immunoassays, next-generation sequencing (NGS), and companion diagnostics, along with strategic expansions like acquisitions, to enhance oncology, neurology, and cardiometabolic testing across hospital networks worldwide.

Merck KGaA (Germany) strengthens its position through its proteomics platforms and liquid biopsy technologies, as well as the acquisition of SpringWorks Therapeutics, which supports the development of precision oncology and immunotherapy biomarkers for biopharma pipelines.

Thermo Fisher Scientific (US) solidifies its leadership by offering integrated NGS, mass spectrometry, and companion diagnostic solutions, including the Clario acquisition, which aids comprehensive biomarker workflows from discovery to deployment.

Abbott (US) expands its capabilities through a robust portfolio of immunoassays and molecular diagnostics, further strengthened by the acquisition of Exact Sciences, to enhance cancer screening and multi-disease early detection in reference labs globally.

QIAGEN (Netherlands) complements these efforts with sample preparation technologies, multi-omics kits, and PCR-based assays that streamline biomarker validation and companion diagnostics for infectious diseases, oncology, and transplant monitoring.

Related Reports:

Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]